Mentalising impairments in somatic symptom and functional neurological disorders: A systematic review.

J Psychosom ResApr 29, 2026 (epub)
Clinical ResearchPsychiatry

Maria Stagaki, Julia Griem, Tobias Nolte et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review examined mentalizing impairments in individuals with Somatic Symptom Disorder (SSD) and Functional Neurological Disorder (FND) compared to healthy and clinical controls. Analyzing 18 studies with 1801 participants, it found that adults with SSD and FND, especially those with psychogenic non-epileptic seizures, exhibited significant deficits in other-focused cognitive mentalizing.

Key findings

  • Adults with SSD and FND showed impairments in other-focused cognitive mentalizing compared to control groups.
  • The review included 18 studies with a total of 1801 participants.
  • Self-focused mentalizing was rarely assessed, limiting conclusions on this aspect.

Why it matters

Understanding mentalizing impairments in SSD and FND can inform clinical assessments and interventions, potentially improving patient outcomes by addressing underlying cognitive deficits.

What to keep in mind

Substantial diagnostic and measurement heterogeneity was noted, indicating variability in study quality and methodologies.

Source

PubMed · PMID 42070419

Published in J Psychosom Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.